Blockchain Registration Transaction Record

Kiora's KIO-300 Suppresses Seizure Activity in Preclinical Epilepsy Model

Kiora Pharmaceuticals reports preclinical data showing KIO-300 suppresses seizure activity in an epilepsy model, presented at the Epilepsy Foundation Pipeline Conference. Learn about the dual potential of this ion channel modulator.

This news matters because epilepsy affects approximately 50 million people worldwide, and current treatments often fail to control seizures or cause significant side effects. Kiora's KIO-300, derived from a platform already in clinical trials for blindness, offers a potential new mechanism—ion channel modulation—that could lead to more effective and better-tolerated therapies. The dual application of this molecule across eye and brain disorders highlights the promise of targeted small molecules in addressing complex neurological conditions. For investors and patients, this represents a potential expansion of Kiora's pipeline into a massive unmet medical need, with early data suggesting efficacy in a key epilepsy model.